Case Study: Sanofi achieves scalable, risk-based de-identification of clinical trial data with Privacy Analytics

Sanofi - Customer Case Study

Sanofi worked to share clinical trial data with researchers while protecting participant privacy and meeting de-identification requirements. The challenge was to make individual participant data from its Fluzone vaccine trial available for secondary research without exposing personal or protected health information. Privacy Analytics supported this effort using its de-identification methodology and software.

Privacy Analytics analyzed the Fluzone dataset, calculated an acceptable re-identification risk threshold of 0.075, and applied targeted de-identification and text redaction techniques to reduce risk while preserving utility. The original dataset’s risk was 0.14, and Privacy Analytics reduced it to 0.06, below the threshold. The case study also showed that rule-based methods from other approaches left risk at 0.082, demonstrating the value of Privacy Analytics’ risk-based process.

Sanofi

Robin Jenkins

Senior Director Program Management